Posted by Michael Wonder on 22 Jul 2016
Two new medicines for advanced kidney cancer
21 July 2016 - Cabometyx and Kisplyx provide additional treatment options for patients with unmet medical need.
The EMA has recommended granting marketing authorisations in the European Union for two medicines for the treatment of advanced renal cell carcinoma (kidney cancer).
Cabometyx (cabozantinib) and Kisplyx (lenvatinib) are indicated for the treatment of adult patients with advanced renal cell carcinoma who have been previously treated with a vascular endothelial growth factor (VEGF)-inhibitor; Cabometyx is to be used as monotherapy while Kisplyx is for use in combination with everolimus.
